{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-078603","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.967323+00:00","generated_at":"2026-05-17T11:23:47.659019+00:00","sec_items":["2.01","3.02","3.03","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vyome Holdings (HIND) completes merger and asset sale, appoints new CEO and board","bullets":["Merger closed: Vyome Therapeutics becomes subsidiary; company renamed Vyome Holdings, Inc.","Asset sale: ReShape sold its assets to Biorad for $2.25M cash, assuming substantially all liabilities.","Reverse stock split: 1-for-4 split effective Aug 15, 2025 to meet Nasdaq minimum bid price.","Leadership: New CEO Venkateswarlu Nelabhotla, interim CFO Robert Dickey; six new directors appointed.","Equity sale: 529,137 shares sold at $11.02 per share in unregistered offering post-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-078603","json":"https://secwatch.observer/filing/0001213900-25-078603.json","markdown":"https://secwatch.observer/filing/0001213900-25-078603.md","text":"https://secwatch.observer/filing/0001213900-25-078603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/ea0253813-8k_vyome.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:23:47.659019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92dc4613f45939738d7bb62daea179d881cd47c1","claim":"Vyome Holdings, Inc: Filed Certificate of Ninth Amendment to change corporate name to Vyome Holdings, Inc. and set board composition with six directors in three classes (effective 2025-08-15).","evidence_excerpt":"a Certificate of Ninth Amendment (the “Certificate of Ninth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, to change its corporate name to Vyome Holdings, Inc. and set forth the Combined Company’s composition of board of directors which will be initially comprised of six directors and divided into three classes with staggered three-year terms","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-15"}],"fact_type":"governance_change"},{"claim_id":"f2aa2c3b5b58ad70f9991444a940da15d408d2eb","claim":"Vyome Holdings, Inc: Filed Certificate of Eighth Amendment to effect 1-for-4 reverse stock split (effective 2025-08-15).","evidence_excerpt":"on August 15, 2025 the Company filed a Certificate of Eighth Amendment (the “Certificate of Eighth Amendment”) with the Secretary of State of the State of Delaware to amend the Company’s Restated Certificate of Incorporation, as amended, and effected the Reverse Stock Split on August 15, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-15"}],"fact_type":"governance_change"},{"claim_id":"c3dc543d5674ec808695c6325b6b9f72f0d7e62b","claim":"Vyome Holdings, Inc completed an acquisition involving Vyome Therapeutics, Inc. (closed 2025-08-15).","evidence_excerpt":"On August 15, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the “Company”) completed the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc. (“Vyome”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Vyome Therapeutics, Inc."},{"label":"Closing","value":"2025-08-15"}],"fact_type":"ma_transaction"},{"claim_id":"c87370b3ba09ff0d806e82e3fa21bd7220cc79bf","claim":"Vyome Holdings, Inc completed a disposition involving Ninburgh Health International Limited for $2.25 million in cash (closed 2025-04-25).","evidence_excerpt":"Asset Purchase Agreement, ReShape sold its assets (excluding cash) to Biorad, and Biorad assumed substantially all of ReShape’s liabilities, for an agreed upon purchase price of $2.25 million in cash, subject to adjustment based on ReShape’s actual accounts receivable and accounts payable at the closing, compared to such amounts as of March 31, 2024.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/0001213900-25-078603-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Ninburgh Health International Limited"},{"label":"Consideration","value":"$2.25 million in cash"},{"label":"Closing","value":"2025-04-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}